7th Jun 2007 07:02
Minster Pharmaceuticals PLC07 June 2007 For immediate release 7 June 2007 MINSTER PHARMACEUTICALS PLC ("Minster" or "the Company") Presentation at the American Headache Society Annual Scientific Meeting Minster Pharmaceuticals plc (AIM: MPM), the drug development companyspecialising in neurological and psychiatric disorders, is pleased to announcethat Professor Peter Goadsby, the principal investigator in the Company's recentclinical trial of tonabersat in the prevention of migraine, will deliver apresentation at the 49th Annual Scientific Meeting of the American HeadacheSociety on Saturday 9 June 2007 in Chicago, Illinois. The presentation by Prof Goadsby, who is Professor of Neurology at the Instituteof Neurology in London, will form part of a prestigious late-breaking session.The presentation will focus on the positive trial data from a Phase IIa study oftonabersat in the prevention of migraine, the initial findings from which wereannounced earlier this year. Further details about the American Headache Society meeting are available fromthe organisation's website, www.americanheadachesociety.org. For further information: Minster Pharmaceuticals plc Tel: +44 (0) 1799 506623Paul Sharpe, Chief Executive OfficerRobert Aubrey, Chief Financial Officer Buchanan Communications Tel: +44 (0) 20 7466 5000Mark Court/ Rebecca Skye Dietrich Nomura Code Securities Limited Tel: +44 (0) 20 7776 1200Chris CollinsRichard Potts Notes for editors: About Minster Pharmaceuticals plc Minster Pharmaceuticals is a drug development company focussed on neurologicaland psychiatric disorders. Its principal pipeline assets are tonabersat, underdevelopment in the preventive treatment of migraine, and sabcomeline inschizophrenia. Worldwide rights to both compounds were acquired fromGlaxoSmithKline and the compounds benefit from comprehensive safety tolerancedata as a result of investment by GSK. Tonabersat is the most advanced compound in an exciting new class of drugscalled gap junction blockers, which have significant potential in the preventionof migraine and other major neurological conditions. Sabcomeline, a muscarinicpartial agonist, has potential in the treatment of chronic schizophrenia. Minster's near-term focus is on the development and commercialisation of itscurrent pipeline. Its medium term strategy is to leverage the anticipatedcashflows from the current pipeline by in-licensing further compounds with theultimate objective of creating a substantial and highly efficient drugdevelopment enterprise focussed on the central nervous system. Minster joined the AIM market in February 2005 and trades under the symbol MPM.For further information please visit www.minsterpharma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
MPM.L